Skip to content

Is it now time to prepare psychiatry for a psychedelic future?

David Nutt, Ilana B Crome, Allan H. Young

The British Journal of Psychiatry May 20, 2024 DOI: 10.1192/bjp.2024.76 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Review Peer reviewed
Topics Depression MDMA Psilocybin PTSD
Keywords Psychedelics Mental healthcare Psychedelic treatment MDMA Ecstasy Psilocybin magic
Citations 18
Key findings Australia's rescheduling of psilocybin and MDMA creates both opportunities and challenges for psychiatry communities and health systems in responding to these developments.

Abstract

Australia has just rescheduled two drugs controlled under the United Nations Psychotropic Drug Conventions, psilocybin and MDMA, as treatments for treatment-resistant depression and post-traumatic stress disorder respectively. This feature explores the reasons for these developments, the opportunities and challenges they provide to psychiatry communities and how along with health systems these communities might respond to these developments.

In the evidence

This study is part of the evidence base for 2 syntheses in the library. Here is how each one recorded it.

  • Argues that Australia's rescheduling of psilocybin and MDMA as treatments for treatment-resistant depression and PTSD creates both opportunities and challenges for psychiatry and health systems.

    Synthesized

  • Explores opportunities and challenges for psychiatry after Australia rescheduled psilocybin and MDMA as treatments for treatment-resistant depression and PTSD respectively.

    Synthesized

Comparable studies

Other narrative reviews on psilocybin for PTSD, most cited first.

Explore topics

By condition and practice